DUBLIN, June 3, 2019 /PRNewswire/ -- Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment
of Robert Iannone, M.D., M.S.C.E.,
as executive vice president, research and development, effective
May 29, 2019. Dr. Iannone will lead
Jazz's growing global R&D organization, including the
pre-clinical development, clinical development, clinical
operations, biostatistics, medical affairs, regulatory affairs,
pharmacovigilance and safety functions.
"Rob's extensive industry knowledge, leadership experience and
strategic insights bring expertise in areas critical to our
expanding capabilities as an innovative, global biopharmaceutical
company with growing R&D investment and portfolio," said
Daniel Swisher, president and chief
operating officer at Jazz Pharmaceuticals. "I look forward to Rob's
leadership to propel Jazz forward in the identification and
development of life-changing medicine for people with limited or no
options."
Dr. Iannone joins Jazz from Immunomedics where he served as the
chief medical officer and head of R&D. Prior to his role at
Immunomedics, Dr. Iannone had leadership assignments across early-
and late-stage development, including the development and approval
of immuno-oncology medicines at AstraZeneca and Merck &
Co. At AstraZeneca, he served as senior vice president and
head of immuno-oncology, global medicines development. At
Merck & Co., Dr. Iannone was the executive director for
clinical research and section head of oncology.
"I am excited to join Jazz at this time to work with its growing
R&D team to further advance the company's mission and its
transformation into a leading integrated biopharmaceutical
company," said Dr. Iannone. "The company's evolving pipeline and
deep relationships in the sleep and oncology medical communities
are a testament to Jazz's commitment to advancing science to
address unmet needs for patients."
Dr. Iannone received his M.D. from Yale
University School of Medicine with Alpha Omega Alpha honors and a Master of Science
in Clinical Epidemiology from the University
of Pennsylvania School of Medicine. Dr. Iannone completed
his pediatric residency and pediatric hematology-oncology
fellowship at Johns Hopkins Hospital, and has held faculty
positions in pediatrics at the University of
Pennsylvania School of Medicine and Children's Hospital of
Philadelphia. Dr. Iannone is the
author or co-author of numerous articles in peer-reviewed journals
and has served on the Biomarkers Consortium of the Cancer Steering
Committee of the Foundation for the National Institutes of Health
since 2011.
Jazz is actively exploring innovative therapeutic options
ranging from small molecule advancements to biologics, and novel
compounds within hematology/oncology and sleep medicine.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical
company, is dedicated to developing life-changing medicines for
people with limited or no options. As a leader in sleep medicine
and with a growing hematology/oncology portfolio, Jazz has a
diverse portfolio of products and product candidates in
development, and is focused on transforming biopharmaceutical
discoveries into novel medicines. Jazz Pharmaceuticals markets
Xyrem® (sodium oxybate) oral solution,
Erwinaze® (asparaginase Erwinia chrysanthemi),
Defitelio® (defibrotide sodium) and Vyxeos®
(daunorubicin and cytarabine) liposome for injection in the U.S.
and markets Erwinase®, Defitelio®
(defibrotide) and Vyxeos® 44 mg/100 mg powder for
concentrate for solution for infusion in countries outside the U.S.
For country-specific product information, please visit
www.jazzpharmaceuticals.com/medicines. For more information, please
visit www.jazzpharmaceuticals.com and follow us on Twitter at
@JazzPharma.
"Safe Harbor" Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements, including,
but not limited to, statements related to the company's future
product development activities and objectives and other statements
that are not historical facts. These forward-looking statements are
based on the company's current plans, objectives, estimates,
expectations and intentions and inherently involve significant
risks and uncertainties. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks and
uncertainties associated with: pharmaceutical product development
and clinical success thereof; the regulatory approval process;
effectively commercializing new products; and other risks and
uncertainties affecting the company and its development programs,
including those described from time to time under the caption "Risk
Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and
Exchange Commission filings and reports (Commission File No.
001-33500), including the company's Quarterly Report on Form 10-Q
for the quarter ended March 31, 2019
and future filings and reports by the company. Other risks and
uncertainties of which the company is not currently aware may also
affect the company's forward-looking statements and may cause
actual results and the timing of events to differ materially from
those anticipated. The forward-looking statements herein are made
only as of the date hereof or as of the dates indicated in the
forward-looking statements, even if they are subsequently made
available by the company on its website or otherwise. The company
undertakes no obligation to update or supplement any
forward-looking statements to reflect actual results, new
information, future events, changes in its expectations or other
circumstances that exist after the date as of which the
forward-looking statements were made.
Logo -
https://mma.prnewswire.com/media/272253/Jazz_Pharmaceuticals_Logo.jpg